CN112129950B - 一种检测白介素6的磁微粒化学发光试剂盒 - Google Patents
一种检测白介素6的磁微粒化学发光试剂盒 Download PDFInfo
- Publication number
- CN112129950B CN112129950B CN202010951772.9A CN202010951772A CN112129950B CN 112129950 B CN112129950 B CN 112129950B CN 202010951772 A CN202010951772 A CN 202010951772A CN 112129950 B CN112129950 B CN 112129950B
- Authority
- CN
- China
- Prior art keywords
- interleukin
- magnetic particle
- enzyme
- labeled antibody
- buffer solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004889 Interleukin-6 Human genes 0.000 title claims abstract description 42
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 42
- 229940100601 interleukin-6 Drugs 0.000 title claims abstract description 38
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 32
- 102000004190 Enzymes Human genes 0.000 claims abstract description 31
- 108090000790 Enzymes Proteins 0.000 claims abstract description 31
- 239000007853 buffer solution Substances 0.000 claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- 239000000725 suspension Substances 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000003223 protective agent Substances 0.000 claims abstract description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 5
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 5
- 239000002981 blocking agent Substances 0.000 claims description 22
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 238000003908 quality control method Methods 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- QDSRPZLVNAXMTL-UHFFFAOYSA-N 2-chloro-1-[4-(4-nitrophenyl)piperazin-1-yl]ethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCN(C(=O)CCl)CC1 QDSRPZLVNAXMTL-UHFFFAOYSA-N 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108010062374 Myoglobin Proteins 0.000 claims description 3
- 102000036675 Myoglobin Human genes 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 108010058846 Ovalbumin Proteins 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- 102000009843 Thyroglobulin Human genes 0.000 claims description 3
- 108010034949 Thyroglobulin Proteins 0.000 claims description 3
- 108060003552 hemocyanin Proteins 0.000 claims description 3
- 229940092253 ovalbumin Drugs 0.000 claims description 3
- 229960002175 thyroglobulin Drugs 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229920002366 Tetronic® 1307 Polymers 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 25
- 230000035945 sensitivity Effects 0.000 abstract description 24
- 239000004094 surface-active agent Substances 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000035484 reaction time Effects 0.000 abstract description 4
- 239000000872 buffer Substances 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229920002359 Tetronic® Polymers 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 238000010989 Bland-Altman Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明涉及一种检测白介素6的磁微粒化学发光试剂盒,包括包被抗白介素6抗体的磁微粒悬浮液、酶标抗体、化学发光底物液和酶标抗体用缓冲液;酶标抗体用缓冲液包含以下浓度组分:磷酸氢二钠25~100mmol/L,磷酸二氢钠25~100mmol/L,氯化钠25~150mmol/L,蛋白保护剂0.5~2wt%,ProClin 300 0.03~0.1wt%,T 1307 1~2wt%,BTA‑40 1~2wt%。本发明通过在酶标抗体用缓冲液通过T 1307与BTA‑40两种表面活性剂联用,增加抗原抗体反应概率的同时加快抗原抗体反应时间,从而提高试剂的灵敏度和准确性。
Description
技术领域
本发明涉及生物物质检测技术领域,尤其涉及一种检测白介素6的磁微粒化学发光试剂盒。
背景技术
白细胞介素-6(Interleukin~6,IL-6)是一种功能广泛的多效性细胞因子。IL-6可调节多种细胞的生长与分化,具有调节免疫应答、急性期反应及造血功能,并在机体的抗感染免疫反应中起重要作用。在炎症反应中,IL-6的升高早于其他细胞因子,也早于CRP和PCT,而且持续时间长,因此可用来辅助急性感染的早期诊断。
目前,IL-6磁微粒化学发光检测试剂盒目前还较少,常见的是酶联免疫吸附试验法(ELISA)试剂盒。该技术的缺点是检测灵敏度较低,重复性差,检测过程耗时长,不利于全自动检测仪器的检测,但临床测试对IL-6试剂的灵敏度和准确性均有较高的要求,高灵敏度对急性感染的早期诊断具有重要作用。国内试剂通常灵敏度较低,对比文献CN109991425A提供了的灵敏度为3.8pg/ml。
发明内容
有鉴于此,本发明提供一种检测白介素6的磁微粒化学发光试剂盒,其检测灵敏度为1.5pg/ml,远高于现有的试剂盒。
一种检测白介素6的磁微粒化学发光试剂盒,包括包被抗白介素6抗体的磁微粒悬浮液、酶标抗体、化学发光底物液和酶标抗体用缓冲液;
其中,所述酶标抗体用缓冲液包含以下浓度组分:
磷酸氢二钠 25~100mmol/L,
磷酸二氢钠 25~100mmol/L,
氯化钠 25~150mmol/L,
蛋白保护剂 0.5~2wt%,
ProClin 300 0.03~0.1wt%,
Tetronic(tm)1307 1~2wt%,
Bio-Terge AS-40 1~2wt%。
进一步的,所述酶标抗体用缓冲液还包含阻断剂,所述阻断剂选自HBR-X、MAK-33-IgG1和小鼠IgG阻断剂中的至少一种,且每一种的浓度均为0.1~1mg/mL。
进一步的,所述阻断剂包含MAK-33-IgG1和HBR-X,且MAK-33-IgG1和HBR-X的浓度为0.1~0.5mg/mL。
更进一步的,所述阻断剂为0.3mg/mL的MAK-33-IgG1和0.3mg/mL的HBR-X。
进一步的,所述酶标抗体用缓冲液还包括以下浓度组分:氯化镁0.001~0.01mmol/L,氯化锌0.01~0.2mmol/L。
具体的,所述磁微粒悬浮液将包含以下浓度组分:
3-[N,N-二(羟乙基)氨基]-2-羟基丙磺酸 25~100mmol/L,
氯化钠 150~300mmol/L,
蛋白保护剂 0.5~2wt%,
ProClin 300 0.03~0.1wt%。
进一步的,所述蛋白保护剂选自牛血清白蛋白、人血清白蛋白、兔血清白蛋白、血蓝蛋白、牛IgG、人IgG、卵清蛋白、肌红蛋白和甲状腺球蛋白中的任一种。
进一步的,所述的磁微粒化学发光试剂盒还包括白介素6校准品和白介素6质控品。
具体的,所述白介素6校准品的配制方法和所述白介素6质控品的配制方法均采用用缓冲液稀释白介素6抗原进行配制;
其中,所述缓冲液是通过在pH为7.4的磷酸盐缓冲液中加入1%~5%的甘油、1%~5%的蔗糖、0.5%~2%的牛血清白蛋白和0.05%ProClinTM300,搅拌溶解后经过0.22μm滤膜处理制备而成。
本发明至少具有以下有益效果:
本发明通过在酶标抗体用缓冲液中使用Tetronic(tm)1307与Bio-Terge AS-40两种表面活性剂联用,增加抗原抗体反应概率的同时加快抗原抗体反应时间,从而提高试剂的灵敏度和准确性。
附图说明
图1为本发明实施例10的试剂盒IL-6测定值与罗氏电化学发光试剂测定的IL-6测定值的线性相关结果图。
图2为本发明实施例10试剂与罗氏试剂的测定结果在统计学一致性结果图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
检测白介素6的磁微粒化学发光试剂盒
本发明提供一种检测白介素6的磁微粒化学发光试剂盒,包括包被抗白介素6抗体的磁微粒悬浮液、酶标抗体、化学发光底物液和酶标抗体用缓冲液;
其中,所述酶标抗体用缓冲液包含以下浓度组分:
磷酸氢二钠 25~100mmol/L,
磷酸二氢钠 25~100mmol/L,
氯化钠 25~150mmol/L,
蛋白保护剂 0.5~2wt%,
ProClin 300 0.03~0.1wt%,
Tetronic(tm)1307 1~2wt%,
Bio-Terge AS-40 1~2wt%。
在本发明提供的上述试剂盒中,按照夹心法的原理对试剂盒组成进行配制,夹心法中纳米磁性微粒(简称磁微粒)包被的抗白介素6抗体、酶标记的抗白介素6抗体与待测样本中的白介素6抗原形成夹心复合物,酶与化学发光底物反应,产生可检测的吸收光。磁球均匀分散在整个反应体系中,由于接触面的影响,待测样本中的白介素6抗原与抗白介素6抗体特异性结合速率越快,即灵敏度越高,越利于检出低浓度的待测抗原。
酶标抗体可以是碱性磷酸酶标记的白介素6单克隆抗体或多克隆抗体(其对应的化学发光底物液是碱性磷酸酶发光底物的溶液),也可以是辣根过氧化物酶标记的白介素6单克隆抗体或多克隆抗体(其对应的底物液是辣根过氧化物酶发光底物的溶液)。
其中,Tetronic(tm)1307是两性表面活性剂,通常作为良好的消泡剂和分散剂。Tetronic(tm)1307可以防止不溶性微粒互相聚集在一起,颗粒越小,分散形成越稳定。Tetronic(tm)1307加入至酶稀释液中,使抗体~碱性磷酸酶标记物分散趋于稳定,增加抗体~碱性磷酸酶标记物与抗原之间的结合概率和结合牢固度。Bio-Terge AS-40是一种温和的阴离子型表面活性剂,它可以加快抗原抗体反应时间,阻止反应物沉淀。Tetronic(tm)1307与Bio-Terge AS-40两种表面活性剂联用,增加抗原抗体反应概率的同时加快抗原抗体反应时间,从而提高试剂的灵敏度和准确性。而常见的表面活性剂如吐温系列(Tween~20、Tween~80)和曲拉通系列(TritonX~114)对提高试剂的灵敏度和准确性没有明显效果。
进一步的,酶标抗体用缓冲液还包括以下浓度组分:氯化镁0.001~0.01mmol/L,氯化锌0.01~0.2mmol/L。
对于酶标抗体用缓冲液包含的组分浓度,磷酸氢二钠浓度还可选自30mmol/L、50mmol/L、60mmol/L、75mmol/L,磷酸二氢钠浓度还可选自30mmol/L、50mmol/L、60mmol/L、75mmol/L,氯化钠浓度还可选自30mmol/L、50mmol/L、60mmol/L、75mmol/L、100mmol/L、125mmol/L,氯化镁浓度还可选自0.002mmol/L、0.003mmol/L、0.004mmol/L、0.005mmol/L、0.006mmol/L、0.007mmol/L、0.008mmol/L、0.009mmol/L,氯化锌浓度还可选自0.02mmol/L、0.04mmol/L、0.06mmol/L、0.08mmol/L、0.01mmol/L、0.012mmol/L、0.014mmol/L、0.016mmol/L、0.018mmol/L,蛋白保护剂浓度还可选自0.6%、0.8%、1.0%、1.2%、1.4%、1.6%、1.8%,PC300的浓度还可选自0.04wt%、0.05wt%、0.06wt%、0.07wt%、0.08wt%、0.09wt%,表面活性剂浓度还可选自1.2wt%、1.4wt%、1.6wt%、1.8wt%。
其中,抗白介素6抗体可以是一种或多种抗白介素6单克隆抗体或抗白介素6多克隆抗体。
其中,酶标抗体用缓冲液还包含阻断剂,阻断剂选自HBR-X、MAK-33-IgG1和小鼠IgG阻断剂中的至少一种,且每一种的浓度均为0.1~1mg/mL。
在日常的临床血清/血浆样本中,有相当比例不同程度的内源性干扰物质,一般包括异嗜性抗体(包括人抗动物抗体如因使用鼠抗体治疗或诊断诱导的抗鼠IgG抗体,以及类风湿因子)等。这些内源性干扰物质导致测定结果的假增高/假阳性或假降低/假阴性,从而影响临床样本测值的准确度及临床样本的相关性。通常在试剂中加入被动或主动类型的阻断剂,以减少样本中的内源性干扰。因此本试剂盒使用了不同的类型及浓度的阻断剂。小鼠IgG主要消除HAMA干扰,但对本试剂盒抗干扰效果不明显。MAK-33-IgG1阻断剂主要消除IgG1的干扰,尤其是单/双价干扰的消除。HBR-X阻断剂能特异性结合人类异嗜性抗体,产生位阻效应,阻止干扰。而将MAK-33-IgG1和HBR-X两种阻断剂混合加入到酶稀释液中,通过调整阻断剂使用浓度可以有效的降低样本内源性干扰对检测系统的影响,提高检测的准确性。
通过上述组分配备,酶标抗体用缓冲液的pH值为6.0~7.5。
具体的,磁微粒悬浮液将包含以下浓度组分:
3-[N,N-二(羟乙基)氨基]-2-羟基丙磺酸(简称DIPSO) 25~100mmol/L,
氯化钠 150~300mmol/L,
蛋白保护剂 0.5~2wt%,
ProClin 300 0.03~0.1wt%。
通过上述组分配备,磁微粒悬浮液的pH值为pH为6.5~8.0。
磁微粒悬浮液组分的浓度,DIPSO的浓度还可选自30mmol/L、50mmol/L、60mmol/L、75mmol/L,氯化钠浓度还可选自160mmol/L、170mmol/L、180mmol/L、190mmol/L、200mmol/L、250mmol/L,蛋白保护剂浓度还可选自0.6%、0.8%、1.0%、1.2%、1.4%、1.6%、1.8%,PC300的浓度还可选自0.04wt%、0.05wt%、0.06wt%、0.07wt%、0.08wt%、0.09wt%。
上述实施例的酶标抗体用缓冲液和磁微粒悬浮液中,蛋白保护剂选自选自牛血清白蛋白、人血清白蛋白、兔血清白蛋白、血蓝蛋白、牛IgG、人IgG、卵清蛋白、肌红蛋白和甲状腺球蛋白中的任一种,以增强包被蛋白和白介素抗体的稳定性。
下面将本发明提供的磁微粒化学发光试剂盒的实施例和对比例列入表1。其中,对比例5中的磁微粒悬浮液采用三羟甲基氨基甲烷(简称THAM)悬浮液。
表1
对白介素6的检测评价
1、评价方案
用实施例1-10和对比例1-5制备好的试剂盒,选择IL-6校准品进行定标后,测试灵敏度和准确度,评价方法如下:
2.1灵敏度评价
测定空白样本、IL-6浓度为1.5pg/mL、1.8pg/mL、2pg/mL的低浓度样本,每个样本测定10次,计算均值、偏差、变异系数,要求CV小于10%且偏差小于10%。
2.2准确度评价
准确度测试所用白介素6参考物质(NIBSC 89/548,m=1.0ug)为冻干粉,测试前,先取1mL超纯水复溶冻干粉,复溶后浓度为1.0ug/mL,然后用5%牛血清将其稀释至1.0ng/mL(稀释1000倍),并稀释至5pg/mL、50pg/mL、500pg/mL,重复测定3次,计算相对偏差=∣测定均值-靶值∣/靶值×100%,要求小于10%。
2.3抗干扰效果评价
取已经经过验证的六份内源性干扰血清(干扰样本)及一份健康无干扰样本(正常样本)作为研究对象,用实施例和对比例制备好的试剂评价抗干扰效果,测试结果与样本实际值偏差。
2.4样本相关性评价
选择50份线性范围在1.5-5000pg/ml内的新鲜血清样本,比较本发明的试剂盒与罗氏公司的白介素6检测试剂盒检测结果的相关性,结果如表4所示。
2.5样本一致性评价
运用Bland-Altman模型评价实施例14试剂与罗氏试剂定量检测结果的一致性。实施例14试剂与罗氏试剂每个样本测值之差与相应两系统测试均值作散点图。用MedCalc15.8软件作Bland-Altman图。观察并分析各点的绝对偏倚分布情况,测得实施例14试剂与罗氏试剂结果差值均值即偏倚(B)及差值标准差(SD),95%的一致性界限位于:B±1.96SD之间。
表2 灵敏度结果
由表2可以看出:
1、实施例的灵敏度优于对比例,实施例的灵敏度可达1.5pg/mL;
2、实施例3-5的灵敏度优于实施例1-2,说明在酶标抗体用缓冲液中添加T1307和BTA-40相对于单一添加,能够提高其灵敏度;
3、实施例6-8的灵敏度效果进一步由于实施例3-5,说明在酶标抗体用缓冲液中进一步添加MAK-33-IgG1、小鼠IgG阻断剂或HBR-X分别作为阻断剂,能够进一步提高其灵敏度;而实施例9-11的灵敏度效果达到最佳,说明在酶标抗体用缓冲液中同时添加MAK-33-IgG1和HBR-X作为阻断剂,能够达到最佳的灵敏度效果,并且MAK-33-IgG1和HBR-X的浓度均为0.3mg/ml时,效果达到最佳;
4、实施例2的灵敏度效果优于对比例5,说明磁微粒悬浮液中DIPSO作为核心缓冲溶液,对免疫磁微粒的灵敏度有提升作用。
表3 准确度结果
由表3可以看出,实施例1-11进行准确度测试,偏差均不超过10%,且其与灵敏度测试表现为相同的趋势,当酶标抗体用缓冲液中添加1%Tetronic(tm)1307、2%Bio-TergeAS-40作为表面活性剂,0.3mg/ml MAK-33-IgG1和0.3mg/ml HBR-X作为阻断剂时,其准确度效果最佳。
表4 抗干扰数据
由表4可以看出,实施例1-8虽然具有一定抗干扰能力,但其测试偏差大部分超过了10%,而实施例9-11采用MAK-33-IgG1和HBR-X作为双阻断剂,测试结果与样本实际值偏差均未超过10%,表明MAK-33-IgG1和HBR-X联用,能够降低内源性物质干扰的产生,并且不会影响正常样本的测试结果,因此提高了结果的准确性。而对比例1-5的抗干扰能力较差。
表5 实施例10试剂与罗氏电化学发光试剂样本相关性
将表5中本发明实施例10的试剂IL-6测定值与罗氏电化学发光试剂测定的IL-6测定值做线性相关性分析,相关性结果如附图1所示,结果为:回归线性方程为Y=0.9406X+12.979,相关系数R2=0.9929。
由此可见,本发明制得的试剂盒测定的IL-6浓度值与罗氏IL-6电化学发光法试剂盒测定的IL-6浓度值具有良好的相关性。
实施例10试剂与罗氏试剂结果差值均值即偏倚(B)为-10.1,差值标准差(SD)为101.9,因此95%的一致性界限范围为-10.1±101.9,实施例10试剂与罗氏试剂的测定结果在统计学上有着一致性,一致性结果如附图2所示。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本发明的保护范围之内。
Claims (6)
1.一种检测白介素6的磁微粒化学发光试剂盒,其特征在于,包括包被抗白介素6抗体的磁微粒悬浮液、酶标抗体、化学发光底物液、酶标抗体用缓冲液;
其中,所述酶标抗体用缓冲液包含以下浓度组分:
磷酸氢二钠 25~100mmol/L,
磷酸二氢钠 25~100mmol/L,
氯化钠 25~150mmol/L,
蛋白保护剂 0.5~2wt%,
ProClin 300 0.03~0.1wt%,
Tetronic 1307 1~2wt%,
Bio-Terge AS-40 1~2wt%;
氯化镁0.001~0.01mmol/L,氯化锌0.01~0.2mmol/L;
所述酶标抗体用缓冲液还包括阻断剂,所述阻断剂包含MAK-33-IgG1和HBR-X,且MAK-33-IgG1和HBR-X的浓度为0.1~0.5mg/mL。
2.根据权利要求1所述的磁微粒化学发光试剂盒,其特征在于,所述阻断剂为0.3mg/mL的MAK-33-IgG1和0.3mg/mL的HBR-X。
3.根据权利要求1所述的磁微粒化学发光试剂盒,其特征在于,所述磁微粒悬浮液包含以下浓度组分:
3-[N,N-二(羟乙基)氨基]-2-羟基丙磺酸 25~100mmol/L,
氯化钠 150~300mmol/L,
蛋白保护剂 0.5~2wt%,
ProClin 300 0.03~0.1wt%。
4.根据权利要求1~3任一项权利要求所述的磁微粒化学发光试剂盒,其特征在于,所述蛋白保护剂选自牛血清白蛋白、人血清白蛋白、兔血清白蛋白、血蓝蛋白、牛IgG、人IgG、卵清蛋白、肌红蛋白和甲状腺球蛋白中的任一种。
5.根据权利要求1所述的磁微粒化学发光试剂盒,其特征在于,还包括白介素6校准品和白介素6质控品。
6.根据权利要求5所述的磁微粒化学发光试剂盒,其特征在于,所述白介素6校准品的配制方法和所述白介素6质控品的配制方法均采用用标准稀释液稀释白介素6抗原进行配制;
所述标准稀释液是通过在pH为7.4的磷酸盐缓冲液中加入1%~5%的甘油、1%~5%的蔗糖、0.5%~2%的牛血清白蛋白和0.05%ProClin 300,搅拌溶解后经过0.22μm滤膜处理制备而成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010951772.9A CN112129950B (zh) | 2020-09-11 | 2020-09-11 | 一种检测白介素6的磁微粒化学发光试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010951772.9A CN112129950B (zh) | 2020-09-11 | 2020-09-11 | 一种检测白介素6的磁微粒化学发光试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112129950A CN112129950A (zh) | 2020-12-25 |
CN112129950B true CN112129950B (zh) | 2023-03-24 |
Family
ID=73845411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010951772.9A Active CN112129950B (zh) | 2020-09-11 | 2020-09-11 | 一种检测白介素6的磁微粒化学发光试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112129950B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113203863B (zh) * | 2021-04-28 | 2022-01-21 | 北京美联泰科生物技术有限公司 | 一种适用于白介素-6检测的缓冲液 |
CN113252905A (zh) * | 2021-05-12 | 2021-08-13 | 北京赛诺浦生物技术有限公司 | 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用 |
CN113640511B (zh) * | 2021-08-04 | 2024-01-30 | 宁波瑞源生物科技有限公司 | 一种磁微粒电化学发光试剂盒 |
CN114216897A (zh) * | 2021-12-22 | 2022-03-22 | 武汉生之源生物科技股份有限公司 | 一种sST2化学发光检测试剂盒及其检测方法 |
CN114544977A (zh) * | 2022-03-25 | 2022-05-27 | 武汉市长立生物技术有限责任公司 | 一种抗凝血酶ⅲ测定试剂盒 |
CN115166244A (zh) * | 2022-06-28 | 2022-10-11 | 北京美联泰科生物技术有限公司 | 一种缓冲液在pgp 9.5检测试剂盒中的应用 |
CN115337679A (zh) * | 2022-08-05 | 2022-11-15 | 美康生物科技股份有限公司 | 一种筛选体外诊断试剂用消泡剂的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2095124B1 (en) * | 2006-12-12 | 2010-10-20 | Response Biomedical Corporation | Multiple analyte immunoassay |
AU2012315784A1 (en) * | 2011-09-28 | 2013-05-16 | Wellstat Diagnostics, Llc | Assay panel for non-alcoholic steatohepatitis |
CN103389383A (zh) * | 2013-08-07 | 2013-11-13 | 上海睿康生物科技有限公司 | 一种测定血清中肌红蛋白含量的检测试剂盒 |
CN103941021B (zh) * | 2014-05-09 | 2017-02-01 | 深圳市国赛生物技术有限公司 | 一种检测白细胞介素‑6的试剂盒以及非诊断目的检测白细胞介素‑6的方法 |
CN107402308A (zh) * | 2017-06-21 | 2017-11-28 | 北京科跃中楷生物技术有限公司 | Il‑6定量检测试剂盒及其制备方法 |
US20210231673A1 (en) * | 2018-08-17 | 2021-07-29 | President And Fellows Of Harvard College | Methods and compositions for detection and quantification of small molecules and other analytes |
WO2020094554A1 (en) * | 2018-11-05 | 2020-05-14 | Protatouans - Etaireia Viotechnologias Monoprosopi Etaireia Periorismenis Eythinis | Method for the detection of analytes in antibody-based assays via a sequential microparticle suspension system |
CN110824159A (zh) * | 2019-11-22 | 2020-02-21 | 蓝怡科技集团股份有限公司 | 一种碱性磷酸酶标记物的稀释液及其应用 |
-
2020
- 2020-09-11 CN CN202010951772.9A patent/CN112129950B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN112129950A (zh) | 2020-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112129950B (zh) | 一种检测白介素6的磁微粒化学发光试剂盒 | |
KR102266095B1 (ko) | 혈청 중의 비정상적인 디카르복실라제 프로트롬빈을 검출하기 위한 단백질 칩, 키트 및 그 제조방법 | |
US4148869A (en) | Immunological reagent and method of using same | |
CN111679086A (zh) | 一种hbp的磁微粒化学发光法检测试剂盒及其制备方法 | |
RU2701684C2 (ru) | Анализ конкурентного связывания с лигандом для обнаружения нейтрализирующих антител | |
US6835543B2 (en) | Step agglutination immunoassay | |
CN110687286A (zh) | 胶乳增强免疫比浊法试剂盒 | |
CN112526140A (zh) | 测定超敏肌钙蛋白t含量的磁微粒化学发光检测试剂盒 | |
CN112014577B (zh) | 一种提高gpc3检测灵敏度的试剂盒及其制备方法 | |
CN113136269A (zh) | 一种用于化学发光免疫检测的清洗液 | |
CN112255416A (zh) | 使用磁微粒化学发光定量检测hbp的试剂盒及其制备、检测方法 | |
CN112129941A (zh) | 一种检测鳞状上皮细胞癌抗原的化学发光试剂盒 | |
CA1080619A (en) | Immunological reagent and method of using same | |
CN113311169A (zh) | 一种测定免疫球蛋白g4的试剂盒及其制备方法 | |
EP0101228B1 (en) | Particle agglutination assay of antigens | |
JP4484924B2 (ja) | 結合対の特異的な結合反応の媒体として使用するための水溶液 | |
CN109324181B (zh) | 一种免疫层析用封闭剂组合物、用途、及免疫层析试剂盒的制备方法 | |
CN117233378B (zh) | 用于抗体定量检测的荧光免疫层析试纸条及其制备方法 | |
CN113671169A (zh) | 用于化学发光免疫检测aep的非特异性吸附清洗液 | |
CN115327137B (zh) | 一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 | |
CN112034178B (zh) | 一种c反应蛋白检测试剂盒 | |
CN113484306B (zh) | 一种磁微粒化学发光清洗液及其制备方法和应用 | |
CA1192133A (en) | Method and reagent for measurement using an enzyme- labelled antibody | |
CN112505331A (zh) | Iv胶原蛋白检测试剂盒 | |
CN114689868A (zh) | 处理剂、用于免疫学检测的试剂盒和免疫学检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |